Early Detection of Cerebral Amyloid Angiopathy (CAA)
Why Amydis?
Amydis is developing an eye test to detect CAA. We developed a tracer, AMDX-2011P, that may enable your doctor to see amyloid deposits in the retina using the same device that is currently used as part of your annual eye health exams. The Company recently completed a Phase 1 clinical trial and now has opened a Phase 2 clinical study of AMDX-2011P in individuals with CAA.
With the help of Amydis’ non-invasive eye test, early diagnosis of CAA may be possible, enabling the opportunity for improved patient care by detecting diseases earlier when they can be most effectively treated.
What is CAA?
Cerebral amyloid angiopathy, or “CAA”, is a condition characterized by an often-silent buildup of toxic amyloid proteins in the brain and eye blood vessels that can be associated with Alzheimer’s disease and brain bleeding. CAA also can be associated with cognitive impairments, including Alzheimer’s type dementia, transient neurological symptoms and other disorders.
CAA is hard to diagnose.
While CAA is often hard to diagnose in older individuals, and even more so in those with dementia, most people with CAA are not aware that they have this disease until symptoms occur. A definitive diagnosis for CAA requires a brain autopsy making it hard to diagnose. There are no widely available simple tests to detect the disease. Currently, doctors use brain imaging and other expensive and invasive procedures to assess a patient’s probability of CAA.